ITM aims to com­pete with No­var­tis af­ter Phase 3 ra­dio­phar­ma win

ITM Iso­tope Tech­nolo­gies Mu­nich plans to seek ap­proval for its β-emit­ting ra­di­oli­gand in gas­troen­teropan­cre­at­ic neu­roen­docrine tu­mors (GEP-NETs) fol­low­ing a Phase 3 suc­cess, the biotech said …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER